Latest news
How Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.stsimplywall.st · Sat, 08 Aug 2026 06:26:15 GMTNeurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 17:19:41 GMTNeurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study - AllSciAllSci · Fri, 07 Aug 2026 16:26:00 GMTNeurocrine starts Phase 1 trial for new obesity drug NBIP-'1968 targeting multiple metabolic pathways. - PluangPluang · Fri, 07 Aug 2026 12:49:32 GMTNeurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC - MarketBeatMarketBeat · Fri, 07 Aug 2026 10:55:54 GMTNeurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 01:53:30 GMTNeurocrine Biosciences (NBIX) CSO Jude Onyia makes bona fide stock gift - Stock TitanStock Titan · Wed, 05 Aug 2026 21:36:27 GMTNeurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount - ChartMillChartMill · Wed, 05 Aug 2026 10:50:43 GMT